linjc16/ctgov huggingface dataset:
Squeaking in Ceramic-on-Ceramic Total Hip Arthroplasty Using Delta TT Cup

Study Overview
=================
Brief Summary
-----------------
This study will evaluate clinical outcome on patients who undergo ceramic on ceramic (CoC) bearing total hip arthroplasty (THA) using Delta TT cup.

Detailed Description
-----------------
This study will evaluate clinical outcome on patients who undergo ceramic on ceramic (CoC) bearing total hip arthroplasty (THA) using Delta TT cup. Specifically the study intends to address the following research topics: The incidence of squeaking after CoC THA using Delta TT cup. The dislocation rate and survival rate of CoC THA using Delta TT cup.

Official Title
-----------------
Squeaking in Ceramic-on-Ceramic Total Hip Arthroplasty Using Delta TT Cup

Conditions
-----------------
Osteoarthritis, Hip, Osteonecrosis of Femoral Head, Femoral Neck Fractures, Rheumatoid Arthritis of Hip, Posttraumatic Arthropathy

Intervention / Treatment
-----------------
* Procedure: Total hip arthroplasty with Delta TT cup


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 18 years old Non-inflammatory degenerative joint disease such as osteoarthritis or avascular necrosis Rheumatoid arthritis Post-traumatic arthritis Fractures of femoral neck Exclusion Criteria: Local or systemic infection Septicaemia Persistent acute or chronic osteomyelitis Confirmed nerve or muscle lesion compromising hip joint function Unstable medical illness Rapidly progressive neurological disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Total hip arthroplasty with Delta TT cup|Total hip arthroplasty using Delta TT cup and ceramic bearings|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Squeaking | Rate of any noise after THA | 6 weeks | 
| Squeaking | Rate of any noise after THA | 3 months | 
| Squeaking | Rate of any noise after THA | 6 months | 
| Squeaking | Rate of any noise after THA | 9 months | 
| Squeaking | Rate of any noise after THA | 12 months | 
| Squeaking | Rate of any noise after THA | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dislocation | Dislocation rate after THA | 6 weeks | 
| Dislocation | Dislocation rate after THA | 3 months | 
| Dislocation | Dislocation rate after THA | 6 months | 
| Dislocation | Dislocation rate after THA | 9 months | 
| Dislocation | Dislocation rate after THA | 12 months | 
| Dislocation | Dislocation rate after THA | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Total hip arhtroplasty, Squeaking, Dislocation, Ceramic bearings
Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This study will determine whether a new diagnostic test called the Cell Search Assay can detect circulating colon cancer cells in patients who have had surgery for colon cancer and had visible cancer removed. Other parts of the study will look at whether the presence of the circulating tumor cells in blood predicts whether a patient will have their colon cancer return.

Official Title
-----------------
Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients

Conditions
-----------------
Colon Cancer

Intervention / Treatment
-----------------
* Procedure: Cell Search Assay


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stage II or III colon cancer Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Cell Search Assay|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colon cancer
400mcg Sublingual Misoprostol as First Line Treatment

Study Overview
=================
Brief Summary
-----------------
Women presenting with incomplete abortion and eligible for treatment with misoprostol were offered 400mcg sublingual misoprostol for treatment. Based on existing literature, the study hypothesises that women can successfully be treated with misoprostol alone as first line treatment.

Official Title
-----------------
Introduction of 400mcg Sublingual Misoprostol as First Line Treatment in 11 Health Posts in Three Districts in Senegal

Conditions
-----------------
Incomplete Abortion

Intervention / Treatment
-----------------
* Drug: Misoprostol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: uterine size less than 12 weeks lmp open cervical os current or past vaginal bleeding willing to provide contact information for follow-up over 18 or with guardian consent Exclusion Criteria: suspicion of ectopic pregnancy intrauterine device in place bad general health (infection, anemia, shoc)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: misoprostol<br>400 mcg misoprostol sublingually | Drug: Misoprostol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete abortion | number of complete abortion with misoprostol treatment alone | 1 year |
A 75 Year Old With Dyspnea a Case Report.Observational Study

Study Overview
=================
Brief Summary
-----------------
Clinical Case report Of spontaneous esophageal perforation in a 75 year old man. He prsented with breathlessness and on investigation found to have esophageal perforation

Detailed Description
-----------------
Boerhaave's syndrome represents a diagnostic dilemma for the physician. Boerhaave's syndrome is an uncommon condition where there is oesophageal rupture following forceful vomiting. We report a case of spontaneous rupture of the esophagus in 75-year-old male with chronic obstructive pulmonary disease who was referred to our hospital with acute onset of breathlessness. The absence of vomiting prior to presentation is the distinguishing feature of this particular case.

Conditions
-----------------
Esophageal Perforation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male with esophageal perforation man with COPD Exclusion Criteria: Iatrogenic perforation
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
esophageal perforation, COPD
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness. Subjects will be randomized to either ABT-652 or placebo in three sequential dosing groups for a 1-week treatment period.

Official Title
-----------------
A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ABT-652 Administered Once Daily to Subjects With an Excessive Daytime Sleepiness Disorder

Conditions
-----------------
Sleep Disorder

Intervention / Treatment
-----------------
* Drug: ABT-652
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Has current diagnosis of an excessive daytime sleepiness disorder, including narcolepsy, idiopathic hypersomnia, and obstructive sleep apnea Age 18 to 60 years Exclusion Criteria Has significant suicidal ideation Has a history of substance abuse Has a history of a certain significant medical conditions, including uncontrolled psychiatric diseases or disorders Use of certain medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days | Drug: ABT-652<br>* See arm description for details<br>Drug: Placebo<br>* See arm description for details<br>|
| Experimental: Arm 2<br>ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days | Drug: ABT-652<br>* See arm description for details<br>Drug: Placebo<br>* See arm description for details<br>|
| Experimental: Arm 3<br>ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days | Drug: ABT-652<br>* See arm description for details<br>Drug: Placebo<br>* See arm description for details<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laboratory Tests |  | Baseline period to end of 1-week treatment period. | 
| ECG |  | Baseline period to end of 1-week treatment period. | 
| Adverse Events |  | Baseline period till 30 days after the last dose. | 
| Vital Signs |  | Baseline period to end of 1-week treatment period. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maintenance Wakefulness Test |  | Baseline period to end of 1-week treatment period. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep disorder
Function and Imaging Assessments for G1961E-associated Stargardt Disease

Study Overview
=================
Brief Summary
-----------------
Some phenotypes of Stargardt disease are rather distinct. This includes the 'bull's eye maculopathy' phenotype associated with the frequent ABCA4 G1961E variant. In anticipation of a treatment trial, this natural history study aims to compare functional and structural outcome measures systematically.

Official Title
-----------------
Function and Imaging Assessments for G1961E-associated Stargardt Disease: Outcome Measure Ranking as Basis for Interventional Trials

Conditions
-----------------
Stargardt Disease, Stargardt Disease 1, Fundus Flavimaculatus, Macular Degeneration, Stargardt, Macular Dystrophy With Flecks, Type 1

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with G1961E-associated Stargardt disease Defined by (1.) the presence of two pathogenic ABCA4 variants with at least one ABCA4G1961E variant, (2.) a Stargardt disease phenotype, and (3.) the absence of pathogenic variants in PRPH2, PROM1, and ELOVL4 Exclusion Criteria: Inability to give informed consent Prior surgery (other than anti-VEGF injections, cataract surgery, YAG laser capsulotomy, or laser retinopexy) that - according to the investigator's judgment - may affect visual function assessments (e.g., retinal detachment surgery, glaucoma filtration surgery, or a history of a corneal transplant in the study-eye) Concurrent ophthalmic conditions in the study eye that (according to the investigator's judgment) may contribute to loss of vision such as clinically significant opacification of the ocular media (corneal dystrophies, cataract), other retinal diseases, or disease of the optic nerve head and visual pathway (including amblyopia) Major surgery planned or other events that (according to the investigator's judgment) could hinder follow-up examinations (e.g., knee replacement)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|According to clinical practice.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression of photoreceptor outer and inner segment loss | Rate of change for the (square-root transformed) EZ loss area (in mm/yr) | Two years from Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stargardt Disease, STGD1, p.Gly1961Glu, G1961E, c.5882G>A
Human Photoallergy Test (824/2016)

Study Overview
=================
Brief Summary
-----------------
To evaluate the potential of a test material to produce a photoallergic response

Official Title
-----------------
Human Photoallergy Test

Conditions
-----------------
Sunscreening Agents

Intervention / Treatment
-----------------
* Drug: BAY987517
* Other: Untreated skin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: be male or female between the ages of 18 and 60 inclusive be lightly pigmented (Fitzpatrick Skin Type I, II, III) have read and signed the written Informed Consent Form and have completed a HIPAA Authorization Form (Health Insurance Portability and Accountability Act) in conformance with 45CFR Parts 160 and 164 be in general good health as determined by the subject's medical history and in the discretion of the investigator Exclusion Criteria: have a visible sunburn have a history of sun hypersensitivity/photosensitivity or photosensitive dermatoses have a known hypersensitivity or allergy against any of the active and non-active ingredients of the investigational products subjects who are employees of the CRO (Contract Research Organization) and/or Bayer or is a household member of an employee

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BAY987517<br>All subjects are patched with the same product | Drug: BAY987517<br>* 50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)<br>Other: Untreated skin<br>* One site is patched without treatment as control<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of skin reactions is evaluated by 5 point scale |  | Up to 72 hours |
Comparison of Central Versus Peripheral Placement of Local Anesthetic

Study Overview
=================
Brief Summary
-----------------
Does ultrasound increases the success rate and if there is a difference in success rate between placing the local anesthetic centrally versus peripherally.

Detailed Description
-----------------
A comparison of the infraclavicular placement of local anesthetic either centrally (posterior cord) vs peripheral placement (lateral or medial cord) using ultrasound guidance. This will be done to determine if ultrasound increases the success rate and if there is a difference in success rate between placing the local anesthetic centrally versus peripherally.

Official Title
-----------------
Selective Local Anesthetic Placement Using Ultrasound-guidance and Neurostimulation for the Infraclavicularbrachial Plexus Block

Conditions
-----------------
Hand Surgery, Elbow Surgery, Forearm Surgery, Wrist Surgery

Intervention / Treatment
-----------------
* Procedure: Peripheral placement of local anesthesia
* Procedure: Central placement of local anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) Class I-III. Patient is undergoing elective hand or forearm surgery. Patient is an adult, 18 years old or older. Exclusion Criteria: Morbid obesity (calculated body mass index > 35 kg/m2). Patient unable to cooperate. Patient with a known brachial plexus injury. Medical contraindication to anesthetic technique (allergy, cardiac condition, neurologic condition, localized infection, bleeding disorder). Patients who are pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Peripheral placement of local anesthesia<br>to receive ultrasound guided peripheral placement of local anesthetic | Procedure: Peripheral placement of local anesthesia<br>* Peripheral placement of local anesthesia<br>|
| Active Comparator: Central placement of local anesthesia<br>to receive central placement of local anesthetic | Procedure: Central placement of local anesthesia<br>* Central placement of local anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| increase success rate of the block to produce surgical anesthesia and analgesia |  | during and following surgical procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
forearm, hand, elbow, wrist, brachial plexus, infraclavicular block
Intra-individual Comparison of Conventional and Digital PET/CT Scanners

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.

Detailed Description
-----------------
There will be a single injection of the PET radiopharmaceutical FDG, followed by a conventional PET/CT scan and a digital PET scan, in this order or vice versa.

Official Title
-----------------
Intra-individual Patient-based Comparison of Conventional and Digital PET/CT Scanners

Conditions
-----------------
Breast Cancer, Lung Cancer, Esophageal Cancer, Miscellaneous Neoplasm

Intervention / Treatment
-----------------
* Diagnostic Test: Digital PET/CT scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria In order to be eligible to participate in this study, a subject must meet all of the following criteria: referred to Isala for a clinically indicated FDG-PET/CT scan suspected or proven lung cancer, esophageal cancer, breast cancer or miscellaneous cancer, either as a primary diagnosis or follow-up study signed informed consent Exclusion criteria A potential subject who meets any of the following criteria will be excluded from participation in this study: age < 18 years incapacitated adults prisoners pregnant patients unable to undergo two consecutive PET/CT scans

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: All included patients will have two PET scans, one on the conventional PET (Ingenuity TF, Philips Healthcare) and one on the digital PET (Vereos, Philips Healthcare). The order of the two PET scans will differ per patient.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients undergo a digital PET/CT<br>Single arm prospective study of paired PET scans. Patients who are referred to the nuclear medicine department to undergo a PET scan, will undergo a PET/CT scan on the conventional scanner as well as the digital PET/CT scanner. | Diagnostic Test: Digital PET/CT scan<br>* The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic outcome of the PET/CT study |  | approximately 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET image quality |  | approximately 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer, Digital pet, Conventional pet